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is specific to sebocytes, not to kerati-
nocytes, and is distinct from effects 
observed with alitretinoin and tretinoin 
that may account, in part, for the supe-
rior efficacy of isotretinoin in reducing 
sebum production.
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Photoadaptation: A Path Toward 
Rational Phototherapy Protocols
Iltefat Hamzavi1
Photoadaptation is defined as the diminished future response to equivalent 
doses of irradiation. It is most often estimated in vivo by looking at changes in 
the minimal erythema dose with subsequent doses of UV radiation. Although 
photoadaptation’s mechanism of action is poorly understood, Palmer et al. 
help clarify the clinical significance of photoadaptation for the dosimetry of 
UV-based phototherapy.
Journal of Investigative Dermatology (2006) 126, 2156–2158. doi:10.1038/sj.jid.5700417
“Doc, I always burn when I go south. Is 
it okay for me to get a base tan before I 
go on vacation so I don’t burn?” “Why is 
the dose of phototherapy increased with 
each treatment, and how do you know 
how much to increase it?”
Clinicians and educators often hear 
these questions from patients and resi-
dents. These questions show an inher-
ent understanding about the basis of 
the work of Palmer et al. (2006) in the 
June issue of the Journal of Investigative 
Dermatology. This phenomenon is 
known as photoadaptation, tolerance, 
accommodation, or acclimatization. 
“Tolerance” and “photoadaptation” 
are the most common terms, and the 
concept has been defined as the “dimin-
ished future response to equivalent doses 
of irradiation” (Oh et al., 2004). It has 
been reported since the beginning of the 
twentieth century and was thought to be 
due to cutaneous pigmentation, epider-
mal hyperplasia, and hyperkeratosis of 
the stratum corneum (Meischer, 1930). It 
is most often estimated in vivo by look-
ing at changes in the minimal erythema 
dose (MED) with subsequent doses of 
UV radiation. Studies such as the work 
reported by Gonzalez et al. (1996) have 
attempted to evaluate the rate of photo-
adaptation by looking at changes in the 
MED. This is a very tedious and labor-
intensive technique but is the basis of the 
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increasing light doses given to patients 
who have phototherapy as well as the 
recommendations on the upper limits of 
phototherapy. However, there were only 
a few patients in these trials, and the 
impact of baseline skin phototype was 
not included in the analysis. The work 
of Palmer et al. (2006) is an advance in 
that it attempts to see whether our pres-
ent recommended phototherapy-dose 
increments are valid. The sample size 
of 352 patients is one of the largest to 
evaluate photoadaptation in real-world 
circumstances. However, there are limi-
tations on what can be drawn from this 
data. First, the end point of adaptation 
as defined as erythema was assessed 
clinically by experienced phototherapy 
technicians and not by the gold standard 
of a subsequent MED on the same body 
site. Second, 40% of patients did not 
have a photoadaptive (that is, erythema) 
response, so their data were excluded 
from analysis. This is one of the greatest 
difficulties with studies on photoadapta-
tion in that there is a great variability in 
the degree of photoadaptation between 
phenotypically similar groups. As a 
result, these data can be used only for 
patients who actually developed ery-
thema. It is difficult to predict what the 
upper or lower limit will be on the basis 
of a patient’s Fitzpatrick skin phototype. 
For the 60% of patients who showed the 
upper limit of photoadaptation in the 
study by Palmer et al. (2006), the recom-
mendation that we start patients at 70% 
of MED and increase their light dose by 
20% would make sense. However, it 
should be kept in mind that there may 
be a significant minority who can toler-
ate larger increments of light. This study, 
as well as others that look at photoadap-
tation, also has limits in its application to 
patient care, as it does not look at pho-
totypes V and VI and thus we have very 
little information to guide our treatments 
in this population. Despite these limita-
tions, this is an impressive effort, and it 
emphasizes the need for further studies 
to determine the appropriate light-dose 
increments for all patients.
It would be helpful to place photoad-
aptation within the context of our pres-
ent use of phototherapy. Phototherapy 
dosimetry is toxicity-limited in that 
the dose delivered is based on how 
much the skin can tolerate. Initially the 
starting dose is based on the MED, which 
is a measure of DNA toxicity (Hamzavi 
and Lui, 2005). In psoriasis, most of the 
toxicity is limited to the normal skin, as 
the MED of the psoriatic plaque is much 
higher than that of normal skin (Trehan 
and Taylor, 2002). In practice, many 
dermatologists do not do an MED as 
the starting point, because of its time-
intensive nature. Most use Fitzpatrick 
skin type questionnaires, because of 
their convenience. However, within 
skin types there is a wide variation in 
the MED, which limits the usefulness of 
the questionnaires used in phototherapy 
dosing (Gordon et al., 1998). Thus most 
patients are started on light doses that 
may not reflect their true sensitivity to 
UV light. Dose increments are another 
factor that determines the efficacy of 
phototherapy for patients, as these are 
often based on the skin types as well. 
With few exceptions, even research 
studies do not look at the impact of 
increasing light doses on the MED 
(Gonzalez et al., 1996). The impact of 
this clinical activity is that too many 
suboptimal treatments may be given 
to phototherapy patients with a slower 
and potentially ineffective treatment 
course. This is expensive to the patient 
in lost time and wages as well as to the 
health-care settings where phototherapy 
is performed. This could be avoided if 
we knew the patient’s baseline MED and 
how this MED changes with subsequent 
doses of UV energy. The work of Palmer 
et al. (2006) is one of the largest studies 
to evaluate this question, and its results 
have an impact on clinicians and basic 
scientists, which brings us to the next 
point and the link between the clinician, 
photoadaptation, and the basic scientist.
The mechanism of photoadaptation 
is only partially understood. It can be 
categorized into pigmentary and non-
pigmentary photoadaptation. Assessing 
photoadaptation in vivo is difficult, as 
it fluctuates greatly among body sites, 
making it hard to compare studies 
(Waterston et al., 2004). The constitutive 
pigment explains much of the difference 
between skin types in regard to initial 
DNA damage by UV irradiation, but 
subsequent protection is not completely 
correlated to increases in pigmentation. 
This is clinically apparent in patients 
with vitiligo who do not repigment with 
therapy but can still tolerate increasing 
doses of UV irradiation (Hamzavi et al., 
2004). Stratum corneum thickening may 
explain some of the increase, but not all, 
as studies have shown that tape stripping 
does not significantly attenuate photoad-
aptation (Gniadecka et al., 1996). When 
controlled for body site, a significant 
component of photoadaptation results 
from the improved ability to repair UV-
induced damage, and this ability is more 
rapid with increasing Fitzpatrick skin 
types (Young et al., 1991). It appears that 
lower skin types tend to have persistent 
DNA damage some time after UV light 
exposure, whereas higher skin types do 
not (Sheehan et al., 2002). This would 
have implications for the dose incre-
ment used in phototherapy, because 
an increase in the MED reflects an 
improved ability to repair DNA dam-
age. However, the fact that DNA dam-
age persists in some populations raises 
a concern about what dose increments 
are appropriate. The work of Palmer 
et al. (2006) along with others helps us 
answer this question, but much more 
work needs to be done to establish prin-
ciples for phototherapy that can be cus-
tomized to each patient.
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Sebaceous Skin Lesions as Clues to 
Hereditary Non-Polyposis Colorectal 
Cancer
Henry T. Lynch1, Ramon M. Fusaro1–3 and Patrick M. Lynch4
Cutaneous lesions consonant with Muir–Torre syndrome strongly suggest 
hereditary non-polyposis colorectal cancer (HNPCC). Ponti et al. discuss the 
importance of combining molecular genetic features of the sebaceous neo-
plasms, including microsatellite instability and immunohistochemistry, with 
family history, to determine the likelihood of HNPCC. Proof of diagnosis is 
identification of one of the mismatch repair germline mutations.
Journal of Investigative Dermatology (2006) 126, 2158–2159. doi:10.1038/sj.jid.5700534
The rarely occurring Muir–Torre syn-
drome (MTS) is a cancer-associated 
genodermatosis characterized by seba-
ceous adenomas, sebaceous carcino-
mas, and multiple keratoacanthomas in 
the presence of visceral cancers integral 
to hereditary non-polyposis colorectal 
cancer (HNPCC), also known as the 
Lynch syndrome. Muir et al. (1967) and 
Torre (1968) were the first to describe 
MTS, although they gave no mention 
of the presence or absence of a fam-
ily history. Subsequent reports of MTS 
involved patients with the above mani-
festations, but family histories were not 
routinely investigated.
Because of our interest in the pattern 
and natural history of multiple primary 
cancers identified in some of these pub-
lished case reports, including carcinoma 
of the colorectum and endometrium and 
other HNPCC tumors, then known as 
the “cancer family syndrome,” we con-
tacted several of these authors to request 
additional information about their cases, 
specifically, whether any of their data 
were consistent with HNPCC. One of 
the authors, a dermatopathologist, kind-
ly advised us about his patient with MTS 
cutaneous signs and visceral cancer 
who, after considerable discussion, had 
stated that she was a member of a very 
large extended family, namely, “Family 
G of Warthin,” which we were studying. 
This family has been under investigation 
for more than 100 years (Douglas et al., 
2005; Lynch and Krush, 1971; Warthin, 
1913). As far as we are aware, this report 
provided the first description of MTS in 
HNPCC (Lynch et al., 1981).
For more than 20 years, sebaceous 
skin tumors and keratoacanthomas 
have been known to be characteristic, 
albeit uncommon, features of HNPCC. 
Since the discovery that germline muta-
tions in members of the mismatch repair 
(MMR) family of genes are responsible 
for HNPCC, a variety of related find-
ings have made the central role of fam-
ily history less critical to the clinical 
diagnosis of HNPCC. Important among 
these has been the recognition that 
the vast majority of tumors in HNPCC 
patients show evidence of microsatellite 
instability (MSI). In turn, MSI has been 
found to correlate very strongly with 
immunohistochemical (IHC) abnor-
malities, specifically loss of staining in 
tumors of those proteins corresponding 
to specific MMR genes. Initially, most of 
these correlations, both MSI and IHC, 
were identified in colorectal cancers. 
More recently it has been observed 
that many of the associated tumors also 
show MSI and loss of expression with 
MMR IHC staining. When the family 
history (for example, Amsterdam I or II 
Criteria, or Bethesda Guidelines; see 
Supplementary Table S1), clinical pic-
ture (early age at onset, right colon pre-
dominance), or histologic features (poor 
differentiation, extracellular mucin, 
tumor-infiltrating lymphocytes) are sug-
gestive of HNPCC, performance of MSI 
testing or IHC is warranted. When infor-
mative, MSI and IHC can lead to effec-
tive germline mutation testing.
Ponti et al. (2006, this issue) describe 
a series of HNPCC families in which a 
small number of cases, about 1%, had 
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